tetano
Editor, Senior Moderator
Biol Pharm Bull
. 2022 Oct 8.
doi: 10.1248/bpb.b22-00470. Online ahead of print.
Safety of remdesivir in 20 children with COVID-19 -case series
Shuji Manabe[SUP] 1 [/SUP], Shinsuke Mizuno[SUP] 1 [/SUP], Tsuyoshi Jinda[SUP] 2 [/SUP], Masashi Kasai[SUP] 1 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19), caused by the SARS-COV-2 virus, has spread worldwide since 2019. Several studies report that adult patients hospitalized with severe COVID-19 can be treated successfully with remdesivir (RDV). However, few studies report the safety and efficacy of RDV for children. This study included 20 hospitalized patients who were diagnosed with COVID-19 and received RDV at Kobe Children's Hospital, Japan, between February and June, 2022. The median age was 2 years (IQR, 1-11 years; range, 5 months to 19 years). Twelve (60%) patients were male. Three (15%) patients were previously healthy, whereas the other 17 had at least one underlying medical condition: five (25%) patients had respiratory disease, four (20%) had cardiac disease, three (15%) had central nervous system disease, four (20%) had hematologic or oncologic disease, and two (10%) had a chromosomal abnormal. All patients recovered without any sequelae, and no serious adverse events were reported. The adverse events were elevated liver enzymes in 4 children (20%), leukopenia (5%), neutropenia (5%), and hypokalemia (5%). Our study may show that the use of RDV for COVID-19 in children led to no serious adverse events.
Keywords: COVID-19; adverse event; pediatrics; remdesivir.
. 2022 Oct 8.
doi: 10.1248/bpb.b22-00470. Online ahead of print.
Safety of remdesivir in 20 children with COVID-19 -case series
Shuji Manabe[SUP] 1 [/SUP], Shinsuke Mizuno[SUP] 1 [/SUP], Tsuyoshi Jinda[SUP] 2 [/SUP], Masashi Kasai[SUP] 1 [/SUP]
Affiliations
- PMID: 36216548
- DOI: 10.1248/bpb.b22-00470
Abstract
Coronavirus disease 2019 (COVID-19), caused by the SARS-COV-2 virus, has spread worldwide since 2019. Several studies report that adult patients hospitalized with severe COVID-19 can be treated successfully with remdesivir (RDV). However, few studies report the safety and efficacy of RDV for children. This study included 20 hospitalized patients who were diagnosed with COVID-19 and received RDV at Kobe Children's Hospital, Japan, between February and June, 2022. The median age was 2 years (IQR, 1-11 years; range, 5 months to 19 years). Twelve (60%) patients were male. Three (15%) patients were previously healthy, whereas the other 17 had at least one underlying medical condition: five (25%) patients had respiratory disease, four (20%) had cardiac disease, three (15%) had central nervous system disease, four (20%) had hematologic or oncologic disease, and two (10%) had a chromosomal abnormal. All patients recovered without any sequelae, and no serious adverse events were reported. The adverse events were elevated liver enzymes in 4 children (20%), leukopenia (5%), neutropenia (5%), and hypokalemia (5%). Our study may show that the use of RDV for COVID-19 in children led to no serious adverse events.
Keywords: COVID-19; adverse event; pediatrics; remdesivir.